Introduction Once thought to be mere cellular debris, exosomes have emerged as significant players in neurodegenerative diseases. These extracellular vesicles, ranging from 30 to 100 nm in size, are produced by all cell types in the central nervous system (CNS). Far from being simple waste disposal units, exosomes are involved in complex intercellular communication and…
Athira Pharma, Inc. (NASDAQ: ATHA), a leading late-stage biopharmaceutical company dedicated to pioneering small molecules that rejuvenate neurons and decelerate neurodegeneration, has unveiled compelling findings from its SHAPE Phase 2 clinical trial. This trial assessed the potential of fosgonimeton (ATH-1017) in patients grappling with Parkinson’s disease, dementia, and dementia with Lewy bodies. Fosgonimeton Fosgonimeton is a…
NATICK, MA, USA, October 31, 2023 /EINPresswire.com/ — NeuroDex, Inc. (“NeuroDex”, or the “Company”), announces that it has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study “Neuronal extracellular vesicles blood-based biomarker for lysosomal function.” This award will enable NeuroDex to utilize its unique ExoSORT™ platform to develop an…
Introduction: Neurodex is pleased to announce its participation in the upcoming 2nd Annual Meeting hosted by the American Association of Extracellular Vesicles (AAEV). Set against the picturesque backdrop of Boston, MA, this event promises to gather esteemed experts in extracellular vesicle research. Neurodex is gearing up to share its latest insights into the study of…
We are delighted to announce that Dr. Erez Eitan, Chief Scientific Officer of NeuroDex, will speak at the upcoming International Society for Extracellular Vesicles (ISEV) Workshop titled “EV-based Biomarkers: Commercialization and Clinical Implementation.” Scheduled to take place in the picturesque city of Aalborg, Denmark, from October 12th to 14th, 2023, this workshop is set to…
In a remarkable stride towards advancing healthcare, Canadian innovators have unveiled a groundbreaking artificial intelligence (AI) program to transform the early detection of Amyotrophic Lateral Sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA) takes immense pride in supporting this revolutionary AI technology, which harnesses the power of AI to scrutinize de-identified electronic medical records (EMRs). This…
Nimbus Therapeutics LLC, a trailblazing player in the pharmaceutical industry, has recently garnered substantial investment from GV, the investment arm affiliated with tech giant Google. The company, known for licensing drugs to industry giants like Gilead Sciences Inc. and Takeda Pharmaceutical Company Limited and forming strategic partnerships with leaders like Eli Lilly and Company, unveiled…
In a groundbreaking move poised to reshape the landscape of brain disease treatments, CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) has announced the successful completion of its merger with EIP Pharma Inc. This milestone marks the birth of a dynamic clinical-stage biotechnology company committed to advancing innovative therapies for degenerative diseases. The company’s press…
Cambridge, MA & Singapore, August 09, 2023 Sunbird Bio, a pioneering biotechnology company focused on advancing the diagnosis and treatment of neurological disorders and early-stage cancer through proprietary protein-based technologies, has successfully merged with Glympse Bio. The merger aims to expedite the development of the two companies protein-based diagnostic platforms, creating a powerful entity named…
Introduction Eli Lilly recently presented the full results from their Phase 3 TRAILBLAZER-ALZ 2 study at the Alzheimer’s Association International Conference (AAIC). The study focused on evaluating the effectiveness of donanemab, a potential treatment for early symptomatic Alzheimer’s disease (AD). The results, also published in the Journal of the American Medical Association (JAMA), demonstrated that…